Quest Diagnostics Incorporated (DGX) Stock

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated is led by CEO James E. Davis, employs 57,000 people, headquartered in Secaucus, US, publicly traded since 1996.

Quest Diagnostics Incorporated (DGX) stock trades at $241.89 with a market capitalization of $26.70B. The stock is valued at a price-to-earnings (P/E) ratio of 24.45, price-to-book of 3.41, price-to-sales of 2.23. Over the past 52 weeks the stock has ranged between $171.18 and $248.84, and currently trades 2.8% below its 52-week high. It pays a dividend yielding 1.47%.

On profitability, Quest Diagnostics Incorporated generates a return on equity (ROE) of 14.49%, return on capital employed of 10.79%, an operating margin of 14.53%, a net profit margin of 9.19%.

In its most recent fiscal year, Quest Diagnostics Incorporated reported annual revenue of $11.0B, net profit of $992.0M. Over the last 5 fiscal years, revenue grew at an average annual rate of 3.2%, and net profit declined at an average annual rate of 7.1%.

The balance sheet shows a debt-to-equity ratio of 0.85, a current ratio of 1.04, total assets of $16.2B, $420.0M in cash and equivalents.

DGX has an average daily trading volume of 1,011,519 shares, a beta of 0.55 (historically less volatile than the overall market).

Quest Diagnostics Incorporated by the numbers, 2016–2025

Between 2016 and 2025 Quest Diagnostics Incorporated reported revenue of $7.5B rising to $11.0B, a change of +46.8% across 10 years. Compounded, revenue has grown 3.2% a year over five years, 3.7% over three, 11.8% over the last twelve months. Net profit rose to $992.0M.

Operating margin went from 17.0% in 2016 to 14.5% in 2025, a fall of 2.5 percentage points. The most recent net margin is 9.19%. On a trailing twelve-month basis to Jun '26, revenue is $11.6B and net profit $1.1B.

Borrowings rose from $3.7B to $6.9B, cash from operations was $1.9B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 17.4% over five years, and was 13.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Quest Diagnostics Incorporated (DGX) — frequently asked questions